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Abstract 
Understanding the mechanisms by which amyloid fibrils are formed, both in vivo and 
in vitro, is vital for developing methods to treat and prevent debilitating deposition 
diseases such as Alzheimer’s disease, Parkinson’s disease, type II diabetes and 
systemic amyloidoses. In recent years, computer modelling and biophysical studies 
have broadened our understanding of the biochemical mechanisms underpinning 
protein aggregation. As a result, it is now believed that the ability to form fibrils is an 
intrinsic property of polypeptide chains and not isolated to disease-related proteins or 
peptides. Molecular chaperones are a diverse group of functionally related proteins 
well known for their ability to suppress amyloid formation, and are likely to be 
important determinants in deciding the fate of protein aggregation prone proteins in 
vivo. Evidence is presented that suggests that there is striking commonality in the 
anti-amyloidogenic activity of molecular chaperones regardless of their structural and 
spatial differences. In this review, we focus on what in vitro biophysical studies tell us 
about amyloid formation and molecular chaperones, and how investigating the role of 
chaperones in fibril formation can enhance our understanding of protein misfolding 
diseases. 
	  




A broad range of human disorders are associated with the formation and deposition of 
structured fibrillar aggregates [1]. These protein deposits may be extracellular, such as 
Aβ peptide plaques associated with Alzheimer’s disease, or they may be deposited as 
part of intracellular inclusions such as in the case of α-synuclein in Parkinson’s 
disease [1]. These “protein deposition diseases” encompass neurodegenerative 
conditions such as Alzheimer’s disease, localised amyloidosis such as type II 
diabetes, and systemic non-neuropathic amyloidoses associated with the proteins 
transthyretin and lysozyme [2]. Although the diseases associated with protein deposits 
are commonly sporadic, there is clear evidence that some familial forms are 
associated with deposition of globular proteins that contain destabilising mutations 
making them more aggregation prone [3-5]. These inherited variants have been 
identified as the major components of fibrillar aggregates found in patients suffering 
from various protein deposition disorders (see [1] for extensive list) strongly 
suggesting that the aggregation of these proteins is intimately linked with pathology. 
Indeed, in lysozyme amyloidosis, amyloid deposits can accumulate in extraordinary 
proportions disrupting the function of whole organs [6]. In other cases, particularly 
neurodegenerative diseases associated with protein deposits, it is now thought that 
small soluble aggregates are the most damaging species; however the precise 
mechanism for toxicity remains unknown [7].	  	  
	  
Despite the lack of a common primary sequence or tertiary structure, the 
various disease associated proteins form fibrils, both in vivo and in vitro, that are 
remarkably similar morphologically [1]. Generally, amyloid fibrils share a common 
cross-β core structure and mature fibrils consist of a number of protofilaments wound 
around each other to form unbranched rope-like fibres of around 7-13 nm in diameter 
(as observed by transmission electron microscopy [8]). Amyloid-like fibrils bind the 
dye Thioflavin T, resulting in an increase in its fluorescence emission [9, 10]; this is 
thought to result from the binding of the dye to the abundant β-sheet structure running 
perpendicular to the long axis of the fibrils [11]. In addition, amyloid deposits have 
the unique property of displaying apple-green birefringence when bound to the	  dye 
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Congo Red [6, 12]. Fibrils formed in vivo are generally found to be associated with 
heparin sulfate proteoglycans, glycosaminoglycans, and a range of other proteins such 
as serum albumin P (SAP) [6, 13, 14] and molecular chaperones  [15]. Although there 
are widely observed, common morphological features that define amyloid fibrils, it is 
becoming increasingly clear that fibrils generated in vitro (even fibrils generated from 
the same protein or peptide under identical conditions) can be heterogeneous in their 
diameter, height, lateral association and periodic twisting [16].	  
	  
In recent years, biophysical studies have helped to broaden our understanding 
of some of the biochemical mechanisms underpinning this highly structured protein 
aggregation process [17]. Typically, amyloid formation follows a kinetic pathway 
similar in nature to protein crystallisation, in which an initial ‘lag’ or nucleation phase 
is followed by a rapid exponential ‘growth’ or polymerisation phase [18, 19]. It is 
thought that the lag phase represents the amount of time required for the formation of 
stable soluble oligomers that can act as the functional nuclei required to seed fibril 
growth. Once a stable nucleus is reached, the formation of mature fibrils is thought to 
occur by rapid association of either monomers or additional oligomers [20]. Recently, 
it has been postulated that fibril breakage, producing a rapid increase in the number of 
growing ends, plays an important role in the rapid kinetics of the growth phase [21, 
22].  
	  
For decades, monomeric disease related proteins have been used as starting 
material to produce fibrils in vitro which bear close morphological similarities to 
those found in in vivo. Indeed, fibrils were made in vitro by proteolytic cleavage of 
Bence Jones proteins as early as 1971 [23] and fibrils were formed in vitro from the 
synthetic Aβ peptide fragment Aβ1-28  even before the full amino acid sequence was 
known for Aβ1-40 and Aβ1-42 [24]. However, more recently, it has become clear that 
fibrils can also be formed in vitro from proteins that have no known association with 
disease (i.e. SH3-PI3 and acylphosphatase) [25, 26], including some that completely 
lack any β-sheet structure (i.e. myoglobin) [27]. It has even been possible to design 
short peptides which can be induced to form fibrils by elevating the incubation 
temperature (coiled coil β peptide; ccβw peptide) [28]. Given the right experimental 
conditions, it appears that many proteins can form amyloid-like fibrils in vitro. It has	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been postulated that the ability of proteins or peptides to form amyloid fibrils is a 
generic feature of the polypeptide chain and therefore, is common to all proteins [17, 
29]. Experiments investigating the effects of point mutations in acylphosphatase on 
aggregation rates showed that these rates correlated with physicochemical effects 
such as hydrophobicity, secondary structure propensity and charge [30]. Further 
studies of these factors led to the development of a computational method for 
predicting the propensity of polypeptides to form fibrillar aggregates [31-33].	  	  
	  
Why don’t all proteins form amyloid in vivo? 
	  
The sequence of any given protein will govern its intrinsic stability and hence 
its likelihood of being in a partially unfolded state at any given time. Therefore, some 
proteins are more likely to form amyloid than others. As outlined above, it is thought 
that hydrophobic residues, net charge and secondary structure propensity all 
contribute to a protein’s ability to form amyloid-like fibrils [1]. Recently, 
experimental studies in a Drosophila model of Alzheimer’s disease were carried out 
to determine whether the calculated intrinsic aggregation propensities (Zagg) could 
relate to observable effects in living organisms [34]. Indeed, there was a clear 
relationship between the amount of Aβ1-42 aggregated in Drosophila and the 
calculated aggregation propensity of each of the variants (e.g Aβ1-42 F20E < Aβ1-42 
WT < Aβ1-42 E22G < Aβ1-42 I31E/E22G). A relationship between Zagg of Aβ1-42 
peptide variants and fly longevity was also observed; however, a number of variants 
did not follow this trend. Further analysis revealed a better correlation between 
longevity and the tendency of the variant to form small, soluble aggregates. 
Therefore, it seems possible to predict the propensity of a protein or peptide to form 
ordered aggregates, in vivo, from its primary structure. However, in addition to these 
intrinsic factors, the environmental conditions in which a protein finds itself plays an 
important role in amyloid formation. For example, some proteins, such as β2-
microglobulin, form amyloid fibrils in vitro quite rapidly at pH 2-3 but formation of 
amyloid at neutral pH is extremely inefficient and requires the addition of co-factors, 
agitation, seeding and extended time frames of aggregation [35]. This illustrates the 
importance of environmental conditions on stability of a protein and thus its tendency 
to form fibrils. Consequently, although fibril formation is likely to be a generic 
	   5	  
property of proteins, the conditions that promote the partial unfolding and stimulate 
fibril formation vary greatly from protein to protein. In biological systems there are 
many complex processes in the intra- and extracellular environment that act to 
suppress protein aggregation and accumulation.	  
	  
Molecular chaperones in intracellular and extracellular Quality Control systems. 
Since the correct folding of a protein is fundamental to its function and any 
disturbances in this structure can lead to loss of function and/or inappropriate 
aggregation (both fibrillar and amorphous), much energy is invested in ensuring that 
the transfer of structural information from genes to folded proteins is correctly 
executed.  A range of processes including RNA metabolism and processing, protein 
synthesis and folding, assembly and disassembly, and protein clearance and 
degradation all contribute to the maintenance of protein homeostasis [36]. One of the 
most important elements of the ensemble of machinery responsible for protein 
homeostasis is the molecular chaperones.  
 
Molecular chaperones are a diverse group of proteins that are characterised by 
an ability to selectively recognise and bind non-natively folded proteins in a non-
covalent but stable interaction [37]. They are most well known for their contributions 
to co- and post-translational folding and for their role in the quality control of 
partially unfolded or misfolded proteins. In addition, they are also known to assist in 
assembly and disassembly of large macromolecular complexes and to aid in 
translocation of proteins to various cellular compartments [38]. There are several 
families of molecular chaperones, defined by their size, cellular compartment and 
function that work together to prevent protein aggregation and facilitate the correct 
folding of non-native proteins [39]. All chaperones fall under two broad, functionally 
related categories: folding type and holding type chaperones [40]. In most cases, 
folding type chaperones (e.g Hsp70, Hsp90) facilitate the correct folding of non-
native proteins through regulated binding and release.  In these cases release of 
polypeptides is driven by ATP-dependent conformational changes. This permits 
misfolded proteins to escape their kinetically trapped non-functional conformation 
and reinitiates the folding process [39]. Holding type chaperones (small Hsps; e.g. α-
crystallin, extracellular chaperones; e.g. clusterin) work independently of ATP and 
offer hydrophobic surfaces for binding of unfolded polypeptides.  Their role is 
	   6	  
thought to be to protect partially folded/misfolded proteins from aggregation until 
folding helper chaperones or proteolytic processes are available to either refold or 
degrade the non-native protein client [40, 41]. Another class of folding machinery, the 
chaperonins, are thought to offer large cages in which protein molecules can fold in 
isolation from inappropriate interactions [42]. Although chaperonins are an important 
part of the protein folding machinery, it is estimated that ~ 9-15% of all cellular 
proteins require chaperonin assistance for folding [43]; this review does not provide a 
detailed examination of their involvement in protein aggregation (for a specialist 
review see [44]). 
 
The components and complexity of the network of chaperones depends on the 
compartments in which they operate. In the cytosol it appears some chaperones may 
act as non-native protein scavengers and that binding of cofactors may determine if 
the protein is to be refolded (when bound to cofactors such as Hip or Hop) or 
degraded (when bound to cofactors such as CHIP or BAG-1) [45]. These cofactors 
contain a chaperone binding motif or “adapter” which can bind to a specific site on 
the C-terminus of Hsp70 and Hsp90. The adapter contains a tandem arrangement of 
three degenerate 34 amino acid repeats (tetratricopeptide repeats, TPRs) adjacent to a 
highly charged α-helix [46]. Binding of cofactors CHIP and BAG-1 inhibits the 
refolding activity of chaperones (Hsp70 & Hsp90) and promotes either ubiquitination 
or direct loading of non-native protein onto the proteasome, respectively [45]. In 
contrast, binding of the co-factors Hip and Hop promotes refolding [47, 48].   
 
Other intracellular compartments also have their own distinct chaperone 
networks. In the mitochondria, chaperones of the Hsp70 and Hsp100 family, together 
with the chaperonin Hsp60 and ATP-dependent proteases, promote refolding or 
degradation of misfolded proteins (reviewed in [49]).  The ER also has a well 
characterised chaperone network; including Hsp70 family member BiP, calnexin and 
calreticulin, cofactors such as SIL1, and proteins that contribute to macromolecular 
assembly such as protein disulphide isomerase (PDI) which facilitates disulphide 
bond formation (reviewed in [50]). More recently, a small network of abundant 
extracellular proteins that can act as chaperones, have been identified. These proteins 
(including clusterin, haptoglobin and α2-macroglobulin) are thought to act as holding 
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type chaperones which can promote the degradation of non-native proteins in the 
extracellular space via receptor mediated endocytosis and traffic to lysosomes [41, 51, 
52]. In this way they are thought to protect against protein misfolding and aggregation 
in the extracellular space.  
 
Thus, when considering the propensity of a protein to aggregate one must consider 
that all compartments in living organisms are patrolled by diverse and distinct 
networks of chaperones that are major and important contributors to maintaining 
protein homeostasis in the whole organism and thus aid in the prevention of large-
scale protein aggregation.  
 
What does studying aggregation and chaperones in vitro tell us? 
As mentioned in the previous section, chaperones can prevent aggregation events by 
blocking intermolecular interactions (by “holding” the substrates) or by assisting in 
the refolding of aberrant substrates. To understand how chaperones prevent organised 
aggregation, such as amyloid formation, it is necessary to determine the key aspects 
of their interactions with the aggregating species. Unfortunately, fibrils formed in vivo 
are amongst countless other molecules in a complex and crowded environment, where 
individual and synergistic effects of chaperones and other biological co-factors can 
play a role in preventing or enhancing the process of aggregation. This makes it very 
difficult to study the exact mechanism by which biological molecules can prevent 
protein misfolding; therefore, to gain a more in depth understanding of this process, in 
vitro experiments, with purified proteins are of vital importance. Although attempts 
are made to maintain physiologically relevant conditions for in vitro fibril formation, 
it is not always possible, and destabilising conditions may be required (high 
temperatures, low pH, denaturants) to allow partial unfolding that will promote 
amyloid formation. For most studies, researchers try to ensure that the fibrillar 
products formed in vitro are reasonably similar to those isolated in vivo by carefully 
characterising these end products using a variety of biophysical techniques (as 
described in the introduction). Of course, in vivo, chaperones may also interact with 
other co-factors and/or protein handling processes such as degradative pathways; 
therefore the knowledge gained from in vitro experiments must be considered a snap 
shot of the processes that occur in vivo. The overarching goal of molecular chaperone 
studies is to help us determine how chaperones behave in vivo. Towards this goal, in 
	   8	  
vitro studies can determine how individual chaperones interact with the various 
structurally heterogenous species along the fibril forming pathway to affect fibril 
formation. 
 
A number of research groups have investigated the in vitro effects of different 
chaperones coming from a diverse range of chaperone families, including Hsp70 
members [53-57], Hsp40 alone [58], Hsp90 members [57], small heat shock proteins 
(sHsps) [59-69], apolipoprotein E [70], chaperonins (TRiC) [71], prefoldin [72], 
Hsp104 [73], and extracellular chaperones [15, 74-80] on the process of fibril 
formation of a variety of proteins and peptides (Table 1). A striking pattern is 
apparent from the existing literature with regards to their effects on amyloid 
formation in vitro; regardless of the chaperone tested, there seems to be a remarkable 
commonality in their mode of action. The remainder of this review will examine in 




Chaperones efficiently inhibit the formation of amyloid fibrils in vitro  
In vitro amyloid formation can be followed by light scattering or by increases 
in ThT fluorescence. It has been repeatedly demonstrated that in vitro incubation of 
molecular chaperones with amyloid forming proteins inhibits the formation of highly 
structured amyloid fibrils. Impressively, molecular chaperones have been shown to 
inhibit the formation of amyloid even when present at extremely substoichiometric 
ratios of chaperone-to-amyloid forming protein. For example, small heat shock 
proteins (Hsp20, Hsp 27 and Hsp17.7) have been reported to inhibit the formation of 
Aβ1-40 fibrils when present at an extremely low 1:1000 ratio of chaperone-to-Aβ 
peptide [65]. While α-crystallin, Hsp70, Hsp90, BiP and clusterin have all been 
shown to suppress the formation of fibrils by various proteins or peptides at 
chaperone-to-substrate ratios equal to or lower than 1:50 [53, 57, 61, 66, 79]. 
Although these molecular chaperones are structurally, compartmentally and 
functionally distinct, the fact that they can inhibit the formation of amyloid by 
unrelated proteins and peptides with such efficiency suggests that, at least in these 
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cases, they are acting via a similar mechanism which may involve interactions with a 
structurally homologous aggregating species.  
	  
In addition to insights gained about the mechanism of chaperone action, it is 
sometimes possible to obtain information from such assays on the process of amyloid 
formation itself. Indeed, the fact that chaperones can inhibit fibril formation when 
present at very low chaperone-to-substrate ratios implies that they interact with a 
population of amyloid forming species which is present at very low abundance. It 
follows that only a small proportion of the substrate monomer population contributes 
to the nucleating units that ‘seed’ fibril formation.  This is consistent with data 
demonstrating that to initiate fibril formation, only a very small fraction of the 




Pinpointing the mechanisms of fibril formation prevention 
Based on the current knowledge of amyloid formation kinetics, it is possible to 
identify a number of protein species with which chaperones may interact (Figure 1), 
including: 
1) The monomeric form of the protein or peptide involved in fibril formation; 
interactions here may stabilise the native state thereby preventing partial unfolding, or 
small structural changes which can lead to intermolecular interactions.  
2) Partially unfolded, monomeric intermediates; interactions with intermediates could 
prevent further interactions, including oligomer formation, towards fibril formation. 
3) Oligomeric species; interactions with oligomers could prevent the creation of stable 
nuclei required for ‘seeding’ fibril growth or may inhibit the addition of oligomers to 
protofibrils during the construction of mature fibrils. 
4) Mature fibrils; interactions coupled with disaggregation may shift the equilibrium 
of the process to favour the smaller, less ordered species.  
	  
The remaining sections of the review will draw on the available in vitro data to 
examine the likelihood that interactions with the species identified above mediate the 
effects of chaperones on fibril formation. 
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Molecular chaperones show limited binding to native monomer 
In general, the process of amyloid formation must involve the partial 
unfolding and a marked refolding of the native protein to generate intermediate 
structures with a high proportion of β-structure that can subsequently assemble into 
mature fibrils. This notion is consistent with the observation that amyloid fibrils are 
more likely to form under conditions in which the native state is destabilised, such as 
elevated temperature or low pH [83]. For intrinsically unfolded proteins and peptides, 
there is evidence to suggest that molecular chaperones not only inhibit fibril 
formation but may help to maintain the native secondary structure of a population of 
protein under conditions that would normally see the shifting of its structure to one 
that is predominantly β-sheet. Monomeric Aβ peptide displays a random-coil like CD 
spectrum; however under fibril forming conditions, there is a change in overall 
secondary structure to β-sheet as mature fibrils form. In the presence of αB crystallin, 
the random-coil like secondary structure of Aβ is maintained and this coincides with 
inhibition of fibril formation [66]. In addition, the presence of α-crystallin (including 
both αA and αB crystallins) inhibits the dramatic change in secondary structure of 
ApoC-II which, in the absence of chaperone, progresses from a random coil to a 
structure containing 80-85% β-sheet character under fibril forming conditions [61]. 
Similarly, Hsp70 inhibits the transition of α-synuclein to a structure which is 
predominantly β-sheet [56]. Due to the low effective concentration of chaperones 
needed, it is unlikely that this prevention of structural change is due to interactions 
with the native monomers. Instead, it seems to suggest that the native conformation is 
in equilibrium with a much less populated, metastable, non-natively structured state, 
which leads to the formation of the more stable nucleus and eventually to fibrils. By 
interacting with this small proportion of the protein population, molecular chaperones 
can prevent large-scale changes in secondary structure and thereby alter the Native-
Intermediate-Unfolded equilibrium of the substrate.  
	  
In many studies, direct interactions with the native monomeric state of the fibril-
forming protein and the chaperones of interest have not been investigated. However, a 
small number of studies have investigated these interactions using techniques such as 
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sedimentation velocity centrifugation, 2D NMR studies, dot-blot assays, ELISA pull-
down assays and immunoprecipitation experiments [15, 54, 56, 61, 78-80]. In these 
investigations, no specific interaction between the chaperones and the starting native 
monomeric protein was observed, even when high concentrations of chaperone were 
present. Together with the observation that chaperones can inhibit amyloid formation 
at very substoichiometric chaperone to substrate ratios, these findings further confirm 
that the mechanism of action is not based on the binding of chaperone to native 
substrate monomer. Of course, in general, interactions between the starting 
monomeric forms and chaperones are possible considering that some of the substrates 
are intrinsically unfolded in nature; therefore, weak or non-specific interactions may 
occur, however these cases are likely to involve the presence of excess amounts of 
chaperone-to-substrate [54].  
 
Interactions with partially unfolded monomers 
In some systems, it is possible to measure the appearance of a population of a 
partially unfolded monomeric intermediate prior to fibril formation [5, 84]. As this 
intermediate species is usually very lowly populated, it is possible that chaperones 
may interact at this stage to prevent fibril formation. In amyloidogenic lysozyme 
variants, a transient intermediate species, crucial for in vitro fibril formation, can be 
detected using hydrogen/deuterium exchange monitored by mass spectrometry. If an 
inhibitor binds to the native state of lysozyme, it can abolish or delay the formation of 
this intermediate species by stabilising the native state. Alternatively, stabilisation of 
the transient intermediate would change the equilibrium between the native state and 
the transient intermediate by favouring the formation of the intermediate. Binding of 
the chaperone to either species would also affect the number of sites protected from 
H/D exchange. From our studies of the effect of extracellular chaperones on 
amyloidogenic lysozyme, we observed that while the presence of clusterin can 
efficiently inhibit fibril formation it had no effect on the number of protected sites (in 
either native or intermediate species) nor did it have any effect on the rate of 
intermediate formation as compared to lysozyme alone [79]. Therefore, in the case of 
fibril formation from human lysozyme, it appears that the mode of action of 
chaperone inhibition is downstream of the transition from native to non-native 
monomer.   
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  Interactions with soluble oligomeric species 
It is widely accepted that amyloid formation is a nucleation dependent 
process. Once a “critical nuclei” population is sufficient, fibril elongation proceeds 
rapidly and leads to the formation of mature fibrils [1]. There is mounting evidence 
that chaperones affect fibril formation by binding to, or influencing the formation of, 
functional nuclei [15, 56, 58, 61, 78-80]. Although inhibition of fibril formation can 
be mediated in vitro by substoichiometric amounts of chaperone, the efficiency of the 
chaperone action is dependent upon the timing of its addition to the aggregation 
reaction mixture. A number of groups have investigated the inhibitory effects of 
adding chaperones at various time points along the fibril forming process (i.e. 
beginning of the assay, mid lag phase, mid-elongation phase) [73, 79, 80, 85]. From 
these experiments, it is clear that once fibril formation has begun, chaperones are less 
effective at inhibiting the process. In contrast, when added at the beginning of the 
reactions, chaperones can completely inhibit fibril formation. In the case of the 
extracellular chaperones, clusterin shows some inhibitory effect when added mid-
elongation phase, however, this is soon overwhelmed and fibril formation proceeds, 
whereas for haptoglobin and α2-macroglobulin, addition at this stage has no 
noticeable effect on lysozyme fibril formation [79, 80]. Similarly, haptoglobin and α2-
macroglobulin had little effect on Aβ1-42 fibril formation when added during the 
elongation stage [80]. One interpretation of this is that the rapid increase in the 
number of growing fibril ends, from breakage, overwhelms the chaperones when they 
are present at concentrations that, if added during lag phase, would normally 
efficiently suppress fibril formation. If this were the case one would expect that at 
certain concentrations chaperones would be able to protect against aggregation when 
added in the elongation phase. Interestingly, in some instances, there are reports that 
chaperone addition in the elongation phase can cease additional fibril formation.  
While addition of Hsp70 to α-synuclein at a 1:10 ratio (Hsp70:α-synuclein) 
efficiently inhibits fibril formation when added at the start of the aggregation reaction, 
addition of Hsp70 to the growth phase at a higher concentration giving a ratio of 1:2 
is able to suppress further elongation [85]. Addition of Hsp104 at the mid-elongation 
point during Aβ1-42 aggregation results in a slight decrease of Thio-T fluorescence 
[73, 85].  This suggests that Hsp104 may be acting upon alternate species and is 
consistent with its disaggregation properties [86].  
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Taken together, the above data strongly suggest that chaperones are most 
effective when added early in the lag phase of fibril forming reactions and that their 
inhibitory effects are drastically reduced once the critical nuclei are formed and fibril 
elongation begins. This observation suggests that (i) the increasing number of 
“growing ends” appearing in the growth phase can “overload” molecular chaperones, 
and/or (ii) molecular chaperones interact preferentially with soluble oligomeric 
prefibrillar species. 
	  
Soluble oligomers of amyloid forming proteins are currently the most 
intensely researched species on the amyloid forming pathway. This is because they 
are likely to be both a ‘seeding’ species for the initial elongation of fibrils (for on-
pathway oligomers) and are also thought to be the most toxic of the amyloid species 
[87]. Interestingly, it appears that there are structural features common to all 
oligomeric species regardless of the protein or peptide from which they are formed, 
and that this structural commonality is recognised by the monoclonal antibody known 
as A11 [88]. However, it is likely that the soluble oligomers that are formed (on or off 
the amyloid forming pathway), and that are recognised by the A11 antibody, are a 
heterogeneous mixture of variably sized soluble oligomers rather than one specific 
oligomer of defined size. In vitro studies of various unrelated chaperones indicate that 
a soluble oligomeric species is the most likely species to interact with chaperones 
during amyloid formation. Hsp70 was shown to bind to oligomers of Aβ1-42 and a 
prefibrillar species of α-synuclein [56, 57]. In addition, all three extracellular 
chaperones, α2-macroglobulin, clusterin and haptoglobin, were shown to bind to 
intermediate prefibrillar species [15, 79, 80]. Moreover, the chaperonin TRiC has 
been shown to bind to prefibrillar aggregates of various sizes [71], while prefoldin has 
been shown to interact with large oligomers of Aβ1-42 in vitro (up to 250 kDa in size) 
[72] and Hsp70 and Hsp90 have also been shown to interact with oligomers of Aβ1-42 
[57] .	  
	  
In the case of the extracellular chaperones, ELISA pull down assays have been 
used to detect chaperone/substrate complexes during aggregation reactions of Aβ1-42.  
Interestingly, the time points when these complexes were detected differ for clusterin 
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and haptoglobin or α2M [15, 79, 80]. For the latter chaperones, the complex was 
detected at earlier time points in the fibril inhibition reaction (maximum appearance at 
150 min) whereas clusterin appears to interact with species which are populated later 
on (beyond 300 min). Therefore, although the mechanism of inhibition appears to be 
similar (i.e. interaction with oligomeric species) there may be some variability in the 
size of the oligomers recognised by each specific chaperone.  This is further 
supported by the action of prefoldin, which interacts with Aβ oligomers that are larger 
in size (up to 250 kDa in size) than those usually observed for Aβ1-42 interactions in 
vitro [72]. Taken together, the evidence suggests that within the heterogenous pool of 
oligomeric species present before the critical nuclei are formed, there is a common 
structural element that can be recognised and bound by a range of unrelated 
chaperones. It has recently been predicted that these early oligomeric species expose 
large regions of hydrophobicity relative to their surface area [89] which is of great 
interest as chaperones are thought to bind to their substrates via exposed hydrophobic 
regions [37, 90]. Given that exposing hydrophobic regions on proteins is undesirable, 
both from a protein function and cytotoxicity standpoint, it is not surprising that 
evolution has driven the quality control mechanisms, such as molecular chaperones, 
to recognise and prevent this type of exposure [90]. Since hydrophobicity is a key 
element in the chaperone-substrate interaction, then it makes sense that oligomeric 
species are bound with the highest affinity, since their larger surface area to volume 
ratio compared to mature fibrils would make the hydrophobic residues more 
accessible for interaction. 
	  
Interactions of molecular chaperones with mature fibrils 
In vivo fibrillar protein deposits generally consist of one dominant aggregated 
protein, along with a range of other proteins and molecules. Various chaperones are 
commonly found co-localised with in vivo protein deposits depending on the type of 
deposit and its location [91]. The reason why chaperones are found in protein deposits 
is unclear and the question still remains as to whether chaperones have bound to the 
deposits after they have formed or have been incorporated during the aggregation 
process. It has been observed in solutions containing very low substoichiometric 
ratios (1:500) of clusterin to aggregating Aβ1-42 that clusterin can be co-centrifuged 
with pellets of insoluble Aβ1-42 fibrils [15], yet, in immuno dot blot assays, binding of 
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extracellular chaperones to mature fibrils was not detected [15, 80]. Lastly, a variety 
of in vitro studies have shown that most chaperones do not disaggregate preformed 
fibrils, although Hsp104 has been shown to disaggregate fibrils in an ATP dependant 
fashion [86]. Hsp70 and Hsp90 had no measurable effect on mature Aβ1-42 fibrils [57], 
and neither α2-macroglobulin or haptoglobin had any effect on mature fibrils formed 
by Aβ1-42, calcitonin or ccβw [80].  
It is interesting to note that in some cases chaperones have been observed to 
promote the formation of fibrils. Recent results suggest that Hsp104 speeds up the 
formation of NM (Sup35’s prion domain) fibrils by contributing to the breakage of 
long fibrils into shorter fragments, thus providing more “growing ends” [86]. In 
addition, at very substoichiometric levels (e.g. 1:500 chaperone-to-substrate) the 
extracellular chaperone clusterin promoted the formation of amyloid fibrils with 
increased thioflavin T fluorescence properties of calcitonin, α-synuclein and Aβ1-42 
when compared to controls. Moreover, ApoE and α1-antichymotrypsin (ACT) have 
also been shown under certain conditions to bind Aβ and promote the formation of β-
sheet rich amyloid fibrils, as a consequence both ApoE and ACT have been termed 
“pathological chaperones” (reviewed in [92]). Regardless of the nature of the 
association between chaperones and in vivo protein deposits, the trapping of 
chaperones in these deposits may compromise the net chaperone activity of a system. 
In addition, the co-localisation of chaperones with fibrils in vivo leads to the 
interesting speculation that these chaperones may be labelling fibrils for subsequent 
degradation, although clear evidence of this has not been reported.  
	  
	  
Links between in vitro and in vivo data 
Collectively, the above data indicates that chaperones are able to efficiently 
inhibit the formation of large structured aggregates. Therefore it is not unreasonable 
to think that chaperones should also efficiently inhibit the formation of amyloid in 
vivo. If one considers this to be true then it follows that in order for protein deposits to 
occur in vivo, chaperone machinery must be either overwhelmed or impaired in some 
way. This has been proposed previously by Muchowski and Wacker [93] and more 
recently by Morimoto [36] and is consistent with the increase in protein deposits with 
age and the “living on the edge theory”. The living on the edge theory stems from 
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recent observations that levels of gene expression are correlated with the in vitro 
aggregation propensity of the respective gene products [94]. The authors conclude 
that individual proteins have evolved to efficiently function at levels within the cell 
that border on their respective thresholds for aggregation. This “life on the edge” 
dictates that any deviation from normal conditions, such as increased expression, 
oxidative stress, or a mutation that destablilizes the protein, could potentially cause 
the protein to aggregate and result in disease. This elegant theory may explain why, as 
human beings age, they are more likely to acquire protein deposition diseases. In fact, 
recent data from an Amyotrophic Lateral Sclerosis (G93A SOD1) mouse model 
shows that although mutant SOD1 interacts with chaperones during early 
presymptomatic stages, insoluble deposits only form in ageing mice. This suggests 
that cells become progressively less efficient at handling misfolded proteins with age 
[95]. Moreover, genetic polymorphisms that produce even marginally unstable 
proteins have been shown to contribute to the overloading of the protein folding 
network to generate insoluble protein aggregates in C. elegans expressing poly Q 
proteins [96]. This is supported by the observation that increases in the levels of Aβ1-
42 protein as small as 1.5 fold are enough to result in Aβ pathology (reviewed in [97]). 
Indeed, inducing the heat-shock response with the small molecule, arimoclomol, 
delayed disease progression in a mouse model of ALS by rescuing motor neurones 
from cell death [98]. Similarly, down regulation of small heat shock proteins 
decreased the lifespan of C. elegans expressing Huntington’s-like polyglutamine 
repeat proteins [99], while directed expression of Hsp70 in α-synuclein-expressing 




In conclusion, studies of the effects of chaperones on amyloid formation in vitro have 
not only increased our knowledge of chaperone function but have also advanced our 
understanding of amyloid formation and disease. In vitro studies have identified 
prefibrillar aggregates (oligomers) as a critical stage in fibril formation and the stage 
at which interactions with chaperones can determine whether the outcome is 
physiological homeostasis or pathology. It is becoming increasingly clear that while 
under normal conditions chaperones and other quality control systems efficiently and 
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rapidly deal with misfolded and partially unfolded proteins, slight variations in the 
structure or expression levels of a protein may overwhelm these systems and lead to 
protein deposition and disease. Collectively, current knowledge indicates that soluble 
protein oligomers are an important target for novel therapeutics in amyloid disease 
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Figure 1: Typical pathway of in vitro fibril formation 
A typical pathway of the stages of in vitro fibril formation of amyloidogenic human 
lysozyme variants. The light scattering curve shows sigmoidal kinetics which is 
representative of a nucleation dependent mechanism. Under physiological conditions, 
the monomeric protein (1) exists in equilibrium between the native, intermediate and 
unfolded states. When fibril forming conditions are applied, a shift in the equilibrium 
increases the population of the intermediate (2) (in the case of human lysozyme this is 
a transiently populated, partially unfolded species) which can further interact to form 
a heterogeneous mixture of small oligomeric species (3). As these small oligomers 
increase in size and stability, they reach a “critical population”, which acts as the 
nucleus for fibril formation. This is followed by a rapid elongation stage, resulting in 
the identification of mature fibrils by methods such as Thioflavin-T binding and 
transmission electron microscopy (TEM) (4).	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Hsp40 Members Hsp40/Hsp70 
(1:100) 





Polyglutamine 2:1 (with ATP)*; 
1:1 (with and 
without ATP)† 
*[54]; †[55] 
 Ydj1 Prion protein (Ure2) 1:1, 1:2 [58] 
     
Hsp70 Members BiP Ig light chain 1:30, 1:100 [53] 
 Hsp70 Aβ1-42 1:50 (with ATP) [57] 





     
Hsp90 Members Hsp90 Aβ1-42 1:50 (with ATP) [57] 
     
Hsp100 
Members 
Hsp104 Aβ1-42 1:10, 1:1000 
(both with ATP) 
[73] 






  Aβ1-40 1:5
*†; 1:100 
(seeded reaction)‡ 
*[60]; [63]; †[66]; 
‡[67] 
  Apolipoprotein C-II 1:67 [61] 
  α-synuclein 1:4, 1:2 [102] 
  β2-­‐microglobulin	   1:13 [66] 
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 αA-­‐crystallin Aβ1-40 1:1 [64] 
 Hsp17.7 Aβ1-40 1:1000 [65] 
 Hsp20 Aβ1-40 1:1000
*; 1:5† *[65]; †[67] 
 Hsp22 αB-­‐crystallin	  
(R120G	  variant) 
- [68] 
 Hsp25 αB-­‐crystallin	  
(R120G	  variant) 
- [68] 
 Hsp27 Aβ1-40 1:1000
*; 1:5† *[65]; †[67] 









  Calcitonin 1:30, 1:15 [80] 
  ccβw	  peptide	   1:150; 1:30; 1:15 [80] 
  Human lysozyme 
(I59T) 
1:10 [80] 
 Clusterin	   Aβ1-42 1:50
*†; 1:10‡ *[74]; †[15] 
 	   Apolipoprotein C-II 1:90 [78] 
 	   α-­‐synuclein	   1:10, 1:4 [15] 
 	   β2-­‐microglobulin 1:500, 1:100, 
1:50, 1:10 
[15] 
 	   Calcitonin 1:10 [15] 
 	   ccβw	  peptide 1:500, 1:100, 
1:50, 1:10 
[15] 
 	   Human lysozyme 
(I56T, I59T) 
1:100, 1:40, 1:10 [79] 
 	   κ-casein 1:100, 1:50, 1:10, 
1:5 
[15] 
 	   Neuropeptide 106-
126 
1:600 [77] 
 Haptoglobin	   Aβ1-42 1:100, 1:20, 1:10 [80] 
 	   Calcitonin 1:150, 1:30, 1:15 [80] 
 	   ccβw	  peptide	   1:30, 1:15 [80] 
 	   Human lysozyme 
(I59T) 
1:10 [80] 
Others Apoliprotein	  E	   Aβ1-40 1:1000 [70] 
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